Crohn's Disease and Colitis Trial, Recruiting NCT03571373 Sponsor: PIBD-Net Condition: Crohn's Disease and Colitis
Back to Crohns Disease And Colitis

Crohn's Disease and Colitis Trial, Recruiting

NCT03571373
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

Inception Cohort (main study group):

  • Children under 18 years old who have been newly diagnosed with, or are likely to have, inflammatory bowel disease (IBD) — a condition affecting the digestive system
  • The diagnosis must be based on a full set of tests, including physical examination, blood tests, camera examination of the bowel, imaging scans, and tissue samples, following established medical guidelines
  • The diagnosis must have been made or confirmed within 2 months of joining the study
  • All records from the diagnostic tests must be available to be added to the study database
  • Consent from the child (where appropriate) and their parents or guardians must be given before joining
  • For children whose biological samples (such as blood) will be included: IBD treatment must not have been started yet

Safety Registry (separate reporting group):

  • Any child under 19 years old with IBD who experiences certain complications listed on the study's agreed safety monitoring list may be reported to this registry
  • No identifying personal details are required for the initial reporting of new cases

Who may not be able to join:

Inception Cohort:

  • Children or families who are unable to read and understand the study information sheets — for example, due to limited familiarity with the local language — where no family member or health advocate is available to help explain the study fully
  • Cases where the required consent from the child or parents has not been obtained
  • Children who are taking treatments similar to IBD medications but for a different medical condition, or those who have a separate condition that directly affects IBD, such as an immune system disorder or a history of major bowel surgery

Safety Registry:

  • There are no exclusion criteria for the safety registry

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 26 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
PIBD-Net
Registry
ClinicalTrials.gov
Start date
3 January 2017
Est. completion
31 December 2027

Where this trial is recruiting

🇳🇱 Netherlands 🇬🇧 United Kingdom

Primary endpoints

Predictors for outcome and treatment response or non-response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov